Skip to main content
    E

    Enanta Pharmaceuticals Inc (ENTA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.67
    -0.32 (-2.91%)

    Market Cap: $320.09M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Enanta Pharmaceuticals Inc (ENTA) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Enanta Pharmaceuticals (ENTA) trades at 4.8x sales and 3.1x book value. Its P/S of 4.8x is above its 5-year median of 4.7x. Its forward P/E is 44.0x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E44.0x
    Price to sales4.8x
    Price to book3.1x
    PEGN/A
    FCF yield-11.9%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 32.4% below 7.1x and its P/B is 10.7% above 2.8x.

    MultipleCurrent5-year median10-year median
    P/S4.8x4.7x7.1x
    P/B3.1x2.8x2.8x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 3 of the 10 year ends shown that have a P/E, its P/E ranged from 17.2x in 2018 to 38.1x in 2019.

    Year endPriceP/EP/SP/B
    2025$15.77N/A5.4x3.6x
    2024$5.75N/A1.8x1.1x
    2023$9.41N/A2.7x1.8x
    2022$46.52N/A11.7x3.2x
    2021$74.78N/A16.3x4.0x
    2020$42.10N/A8.3x1.9x
    2019$61.7838.1x6.6x2.5x
    2018$70.8317.2x5.9x3.2x
    2017$58.6838.1x8.7x3.5x
    2016$33.50N/A12.7x2.4x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ENTA

    What is ENTA's forward P/E ratio?

    Enanta Pharmaceuticals has a forward P/E ratio of 44.0x.

    Is ENTA stock overvalued?

    GNG's valuation label for ENTA is Fairly valued.

    What is ENTA's price to sales ratio?

    Enanta Pharmaceuticals has a price to sales ratio of 4.8x.